BACKGROUND: Talimogene laherparepvec (TVEC) is an oncolytic herpes virus used as intralesional therapy for patients with unresectable stage IIIB through IV melanoma. We reviewed the standard of care treatment of TVEC at a single institution. METHODS: All patients treated with TVEC for advanced melanoma were retrospectively evaluated from 2015 to 2018. Patient demographics, clinicopathologic characteristics, treatment response, and toxicity were reviewed. RESULTS: Twenty-seven patients underwent therapy with TVEC. Median age was 75 years, and 63% of patients were female. Seventeen (63.0%) patients underwent injections on the lower extremity, four (14.8%) on the upper extremity, four (14.8%) on the head and neck, and two (7.4%) on the trunk. Median number of injections was five. Median follow-up was 8.6 months. Of the 27 patients, 23 patients met the criteria for response analysis with at least 8 weeks follow-up. Ten (43.5%) patients experienced a complete response (CR), three (13.1%) experienced a partial response (PR), and five (21.7%) had stable disease (SD) for an overall response rate of 56.5% (CR + PR) and a disease control rate of 78.3% (CR + PR + SD). Adverse events were mostly limited to mild constitutional symptoms within 48 h of injection. Two patients developed cellulitis treated with oral antibiotics, and one patient underwent excision of a lesion for ulceration and bleeding during therapy. DISCUSSION: TVEC is an effective and well-tolerated intralesional therapy for patients with unresectable stage IIIB through IV melanoma. A CR was achieved in almost half of patients treated. Disease control is seen in the vast majority.
BACKGROUND:Talimogene laherparepvec (TVEC) is an oncolytic herpes virus used as intralesional therapy for patients with unresectable stage IIIB through IV melanoma. We reviewed the standard of care treatment of TVEC at a single institution. METHODS: All patients treated with TVEC for advanced melanoma were retrospectively evaluated from 2015 to 2018. Patient demographics, clinicopathologic characteristics, treatment response, and toxicity were reviewed. RESULTS: Twenty-seven patients underwent therapy with TVEC. Median age was 75 years, and 63% of patients were female. Seventeen (63.0%) patients underwent injections on the lower extremity, four (14.8%) on the upper extremity, four (14.8%) on the head and neck, and two (7.4%) on the trunk. Median number of injections was five. Median follow-up was 8.6 months. Of the 27 patients, 23 patients met the criteria for response analysis with at least 8 weeks follow-up. Ten (43.5%) patients experienced a complete response (CR), three (13.1%) experienced a partial response (PR), and five (21.7%) had stable disease (SD) for an overall response rate of 56.5% (CR + PR) and a disease control rate of 78.3% (CR + PR + SD). Adverse events were mostly limited to mild constitutional symptoms within 48 h of injection. Two patients developed cellulitis treated with oral antibiotics, and one patient underwent excision of a lesion for ulceration and bleeding during therapy. DISCUSSION: TVEC is an effective and well-tolerated intralesional therapy for patients with unresectable stage IIIB through IV melanoma. A CR was achieved in almost half of patients treated. Disease control is seen in the vast majority.
Authors: Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Caroline Robert; Georgina V Long; Benjamin Brady; Caroline Dutriaux; Michele Maio; Laurent Mortier; Jessica C Hassel; Piotr Rutkowski; Catriona McNeil; Ewa Kalinka-Warzocha; Kerry J Savage; Micaela M Hernberg; Celeste Lebbé; Julie Charles; Catalin Mihalcioiu; Vanna Chiarion-Sileni; Cornelia Mauch; Francesco Cognetti; Ana Arance; Henrik Schmidt; Dirk Schadendorf; Helen Gogas; Lotta Lundgren-Eriksson; Christine Horak; Brian Sharkey; Ian M Waxman; Victoria Atkinson; Paolo A Ascierto Journal: N Engl J Med Date: 2014-11-16 Impact factor: 91.245
Authors: Timothy M Pawlik; Merrick I Ross; Marcella M Johnson; Christopher W Schacherer; Dana M McClain; Paul F Mansfield; Jeffrey E Lee; Janice N Cormier; Jeffrey E Gershenwald Journal: Ann Surg Oncol Date: 2005-06-16 Impact factor: 5.344
Authors: Igor Puzanov; Mohammed M Milhem; David Minor; Omid Hamid; Ai Li; Lisa Chen; Michael Chastain; Kevin S Gorski; Abraham Anderson; Jeffrey Chou; Howard L Kaufman; Robert H I Andtbacka Journal: J Clin Oncol Date: 2016-06-13 Impact factor: 44.544
Authors: Cristina O'Donoghue; Matthew C Perez; John E Mullinax; Danielle Hardman; Sean Sileno; Syeda Mahrukh Hussnain Naqvi; Youngchul Kim; Ricardo J Gonzalez; Jonathan S Zager Journal: Ann Surg Oncol Date: 2017-10-10 Impact factor: 5.344
Authors: Hidde M Kroon; Brendon J Coventry; Mitchell H Giles; Michael A Henderson; David Speakman; Mark Wall; Andrew Barbour; Jonathan Serpell; Paul Paddle; Alexander G J Coventry; Thomas Sullivan; Bernard Mark Smithers; John F Thompson Journal: Ann Surg Oncol Date: 2015-11-18 Impact factor: 5.344
Authors: Evan S Weitman; Matthew Perez; John F Thompson; Robert H I Andtbacka; Jo Dalton; Mona L Martin; Talia Miller; Chad Gwaltney; David Sarson; Eric Wachter; Jonathan S Zager Journal: Melanoma Res Date: 2018-04 Impact factor: 3.599
Authors: Emma H A Stahlie; Viola Franke; Charlotte L Zuur; Willem M C Klop; Bernies van der Hiel; Bart A Van de Wiel; Michel W J M Wouters; Yvonne M Schrage; Winan J van Houdt; Alexander C J van Akkooi Journal: Cancer Immunol Immunother Date: 2021-01-28 Impact factor: 6.968
Authors: Michael J Carr; James Sun; Hidde M Kroon; John T Miura; Georgia M Beasley; Norma E Farrow; Paul J Mosca; Michael C Lowe; Clara R Farley; Youngchul Kim; Syeda Mahrukh Hussnain Naqvi; Dennis A Kirichenko; Aishwarya Potdar; Hala Daou; Dean Mullen; Jeffrey M Farma; Michael A Henderson; David Speakman; Jonathan Serpell; Keith A Delman; B Mark Smithers; Brendon J Coventry; Douglas S Tyler; John F Thompson; Jonathan S Zager Journal: Ann Surg Oncol Date: 2020-09-11 Impact factor: 5.344
Authors: Johannes Kleemann; Manuel Jäger; Eva Valesky; Stefan Kippenberger; Roland Kaufmann; Markus Meissner Journal: Cancer Manag Res Date: 2021-07-15 Impact factor: 3.989